UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

The New England journal of medicine, 2019-12, Vol.381 (25), p.2416-2428

2019

Volltextzugriff (PDF)

Landscape of systemic therapy for ovarian cancer in 2019: Primary therapy

Cancer, 2019-12, Vol.125 (S24), p.4582-4586

2019

Volltextzugriff (PDF)

Leptomeningeal metastases arising from gynecological cancers

International journal of clinical oncology, 2020-02, Vol.25 (2), p.391-395

2020

Volltextzugriff (PDF)

Phase II study of a new multidisciplinary therapy using once every 3 week carboplatin plus dose-dense weekly paclitaxel before and after radical hysterectomy for locally advanced cervical cancer

International journal of clinical oncology, 2021-01, Vol.26 (1), p.207-215

2021

Volltextzugriff (PDF)

Clinical practice guideline for the treatment of malignant ascites: section summary in Clinical Practice Guideline for peritoneal dissemination (2021)

International journal of clinical oncology, 2022-01, Vol.27 (1), p.1-6

2022

Volltextzugriff (PDF)

Chemoresistance of Gastric-Type Mucinous Carcinoma of the Uterine Cervix: A Study of the Sankai Gynecology Study Group

International journal of gynecological cancer, 2018-01, Vol.28 (1), p.99-106

2018

Volltextzugriff (PDF)

Phase II trial of paclitaxel, carboplatin, and bevacizumab for advanced or recurrent cervical cancer

Gynecologic oncology, 2019-09, Vol.154 (3), p.554-557

2019

Volltextzugriff (PDF)

Validation of tissue factor pathway inhibitor 2 as a specific biomarker for preoperative prediction of clear cell carcinoma of the ovary

International journal of clinical oncology, 2021-07, Vol.26 (7), p.1336-1344

2021

Volltextzugriff (PDF)

Suppressive effect upon carboplatin hypersensitivity reaction via pegylated liposomal doxorubicin combination therapy

International journal of clinical oncology, 2020-09, Vol.25 (9), p.1718-1725

2020

Volltextzugriff (PDF)

Dose-dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: a retrospective study

International journal of clinical oncology, 2020-03, Vol.25 (3), p.502-507

2020

Volltextzugriff (PDF)

Pelvic fractures after definitive and postoperative radiotherapy for cervical cancer: A retrospective analysis of risk factors

Gynecologic oncology, 2017-12, Vol.147 (3), p.585-588

2017

Volltextzugriff (PDF)

Applicability of the concept of “platinum sensitivity” to recurrent endometrial cancer: The SGSG-012/GOTIC-004/Intergroup study

Gynecologic oncology, 2013-12, Vol.131 (3), p.567-573

2013

Volltextzugriff (PDF)

Effect of prior olaparib maintenance therapy for platinum sensitive recurrent ovarian cancer on response to subsequent platinum‐based chemotherapy

The journal of obstetrics and gynaecology research, 2022-05, Vol.48 (5), p.1248-1254

2022

Volltextzugriff (PDF)

Docetaxel and carboplatin chemotherapy for treating patients with stage IVB or recurrent non-squamous cell carcinoma of the uterine cervix: a phase II study

International journal of clinical oncology, 2021-07, Vol.26 (7), p.1314-1321

2021

Volltextzugriff (PDF)

Tumor size before image-guided brachytherapy is an important factor of local control after radiotherapy for cervical squamous cell carcinoma: analysis in cases using central shielding

Journal of radiation research, 2022-07, Vol.63 (5), p.772-779

2022

Volltextzugriff (PDF)

Association between financial toxicity and health-related quality of life of patients with gynecologic cancer

International journal of clinical oncology, 2023-03, Vol.28 (3), p.454-467

2023

Volltextzugriff (PDF)

Quality of life assessment of cell‐free and concentrated ascites reinfusion therapy during initial treatment for advanced ovarian cancer: A prospective cohort study

The journal of obstetrics and gynaecology research, 2021-04, Vol.47 (4), p.1536-1543

2021

Volltextzugriff (PDF)

Veliparib with frontline chemotherapy and as maintenance in Japanese women with ovarian cancer: a subanalysis of efficacy, safety, and antiemetic use in the phase 3 VELIA trial

International journal of clinical oncology, 2023-01, Vol.28 (1), p.163-174

2023

Volltextzugriff (PDF)

Treatment strategy for locally advanced squamous cell cervical cancer with clinically positive pelvic lymph nodes metastasis

The journal of obstetrics and gynaecology research, 2021-07, Vol.47 (7), p.2442-2448

2021

Volltextzugriff (PDF)

Neoadjuvant chemotherapy with docetaxel and carboplatin followed by radical hysterectomy for stage IB2, IIA2, and IIB patients with non-squamous cell carcinoma of the uterine cervix

International journal of clinical oncology, 2016-12, Vol.21 (6), p.1128-1135

2016

Volltextzugriff (PDF)

Propensity score-matched analysis of systemic chemotherapy versus salvage hysterectomy for persistent cervical cancer after definitive radiotherapy/concurrent chemoradiotherapy

BMC cancer, 2020-11, Vol.20 (1), p.1169-13, Article 1169

2020

Volltextzugriff (PDF)

Survival impact of adjuvant concurrent chemoradiotherapy after radical hysterectomy in FIGO stage IIIC1 cervical adenocarcinoma

International journal of clinical oncology, 2021-07, Vol.26 (7), p.1322-1329

2021

Volltextzugriff (PDF)

A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003/intergroup study)

International journal of clinical oncology, 2019-10, Vol.24 (10), p.1284-1291

2019

Volltextzugriff (PDF)

A preoperative low cancer antigen 125 level (≤25.8 mg/dl) is a useful criterion to determine the optimal timing of interval debulking surgery following neoadjuvant chemotherapy in epithelial ovarian cancer

Japanese journal of clinical oncology, 2016-06, Vol.46 (6), p.517-521

2016

Volltextzugriff (PDF)

Gynecologic Cancer InterGroup (GCIG) Consensus Review for Clear Cell Carcinoma of the Uterine Corpus and Cervix

International journal of gynecological cancer, 2014-11, Vol.24 (9 Suppl 3), p.S90-S95

2014

Volltextzugriff (PDF)

1 – 25 von 224

Suche als RSS-Feed

Aktive Filter

SpracheJapanisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(196)
Mit Volltextzugriff
(187)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

Landscape of systemic therapy for ovarian cancer in 2019: Primary therapy

Leptomeningeal metastases arising from gynecological cancers

Phase II study of a new multidisciplinary therapy using once every 3 week carboplatin plus dose-dense weekly paclitaxel before and after radical hysterectomy for locally advanced cervical cancer

Clinical practice guideline for the treatment of malignant ascites: section summary in Clinical Practice Guideline for peritoneal dissemination (2021)

Chemoresistance of Gastric-Type Mucinous Carcinoma of the Uterine Cervix: A Study of the Sankai Gynecology Study Group

Phase II trial of paclitaxel, carboplatin, and bevacizumab for advanced or recurrent cervical cancer

Validation of tissue factor pathway inhibitor 2 as a specific biomarker for preoperative prediction of clear cell carcinoma of the ovary

Suppressive effect upon carboplatin hypersensitivity reaction via pegylated liposomal doxorubicin combination therapy

Dose-dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: a retrospective study

Pelvic fractures after definitive and postoperative radiotherapy for cervical cancer: A retrospective analysis of risk factors

Applicability of the concept of “platinum sensitivity” to recurrent endometrial cancer: The SGSG-012/GOTIC-004/Intergroup study

Effect of prior olaparib maintenance therapy for platinum sensitive recurrent ovarian cancer on response to subsequent platinum‐based chemotherapy

Docetaxel and carboplatin chemotherapy for treating patients with stage IVB or recurrent non-squamous cell carcinoma of the uterine cervix: a phase II study

Tumor size before image-guided brachytherapy is an important factor of local control after radiotherapy for cervical squamous cell carcinoma: analysis in cases using central shielding

Association between financial toxicity and health-related quality of life of patients with gynecologic cancer

Quality of life assessment of cell‐free and concentrated ascites reinfusion therapy during initial treatment for advanced ovarian cancer: A prospective cohort study

Veliparib with frontline chemotherapy and as maintenance in Japanese women with ovarian cancer: a subanalysis of efficacy, safety, and antiemetic use in the phase 3 VELIA trial

Treatment strategy for locally advanced squamous cell cervical cancer with clinically positive pelvic lymph nodes metastasis

Neoadjuvant chemotherapy with docetaxel and carboplatin followed by radical hysterectomy for stage IB2, IIA2, and IIB patients with non-squamous cell carcinoma of the uterine cervix

Propensity score-matched analysis of systemic chemotherapy versus salvage hysterectomy for persistent cervical cancer after definitive radiotherapy/concurrent chemoradiotherapy

Survival impact of adjuvant concurrent chemoradiotherapy after radical hysterectomy in FIGO stage IIIC1 cervical adenocarcinoma

A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003/intergroup study)

A preoperative low cancer antigen 125 level (≤25.8 mg/dl) is a useful criterion to determine the optimal timing of interval debulking surgery following neoadjuvant chemotherapy in epithelial ovarian cancer

Gynecologic Cancer InterGroup (GCIG) Consensus Review for Clear Cell Carcinoma of the Uterine Corpus and Cervix

Aktive Filter

Suchergebnisse filtern